HomeCompareRVXCF vs EQR

RVXCF vs EQR: Dividend Comparison 2026

RVXCF yields 2500.00% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RVXCF wins by $80609755877.33M in total portfolio value
10 years
RVXCF
RVXCF
● Live price
2500.00%
Share price
$0.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80609755877.37M
Annual income
$74,729,580,081,858,750.00
Full RVXCF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — RVXCF vs EQR

📍 RVXCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRVXCFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RVXCF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RVXCF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RVXCF
Annual income on $10K today (after 15% tax)
$212,500.00/yr
After 10yr DRIP, annual income (after tax)
$63,520,143,069,579,940.00/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, RVXCF beats the other by $63,520,143,069,576,690.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RVXCF + EQR for your $10,000?

RVXCF: 50%EQR: 50%
100% EQR50/50100% RVXCF
Portfolio after 10yr
$40304877938.70M
Annual income
$37,364,790,040,931,290.00/yr
Blended yield
92.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

RVXCF
No analyst data
Altman Z
-94.1
Piotroski
1/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RVXCF buys
0
EQR buys
0
No recent congressional trades found for RVXCF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRVXCFEQR
Forward yield2500.00%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$80609755877.37M$40.5K
Annual income after 10y$74,729,580,081,858,750.00$3,819.61
Total dividends collected$80198875900.38M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: RVXCF vs EQR ($10,000, DRIP)

YearRVXCF PortfolioRVXCF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$260,700$250,000.00$11,248$547.57+$249.5KRVXCF
2$6,370,070$6,091,121.50$12,701$666.53+$6.36MRVXCF
3$145,912,632$139,096,656.81$14,405$814.59+$145.90MRVXCF
4$3,133,830,814$2,977,704,297.75$16,413$999.84+$3133.81MRVXCF
5$63,122,812,060$59,769,613,088.96$18,795$1,232.92+$63122.79MRVXCF
6$1,192,683,724,131$1,125,142,315,226.76$21,639$1,527.95+$1192683.70MRVXCF
7$21,144,559,711,004$19,868,388,126,183.19$25,057$1,903.80+$21144559.69MRVXCF
8$351,818,906,448,043$329,194,227,557,269.44$29,197$2,385.87+$351818906.42MRVXCF
9$5,495,491,397,671,320$5,119,045,167,771,913.00$34,250$3,008.70+$5495491397.64MRVXCF
10$80,609,755,877,367,070$74,729,580,081,858,750.00$40,467$3,819.61+$80609755877.33MRVXCF

RVXCF vs EQR: Complete Analysis 2026

RVXCFStock

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.

Full RVXCF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this RVXCF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RVXCF vs SCHDRVXCF vs JEPIRVXCF vs ORVXCF vs KORVXCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.